News | October 20, 2022

Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections — NDA resubmission expected in Second Half of 2024, if successful– –Oral sulopenem, if approved, could be the first...